251 related articles for article (PubMed ID: 16286432)
1. Systematic review of studies of productivity loss due to rheumatoid arthritis.
Burton W; Morrison A; Maclean R; Ruderman E
Occup Med (Lond); 2006 Jan; 56(1):18-27. PubMed ID: 16286432
[TBL] [Abstract][Full Text] [Related]
2. Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis.
Gwinnutt JM; Leggett S; Lunt M; Barton A; Hyrich KL; Walker-Bone K; Verstappen SMM;
Rheumatology (Oxford); 2020 Oct; 59(10):2908-2919. PubMed ID: 32097471
[TBL] [Abstract][Full Text] [Related]
3. Productivity loss of Japanese patients with rheumatoid arthritis - A cross-sectional survey.
Sruamsiri R; Mahlich J; Tanaka E; Yamanaka H
Mod Rheumatol; 2018 May; 28(3):482-489. PubMed ID: 28849715
[TBL] [Abstract][Full Text] [Related]
4. Longterm Work Productivity Costs Due to Absenteeism and Permanent Work Disability in Patients with Early Rheumatoid Arthritis: A Nationwide Register Study of 7831 Patients.
Martikainen JA; Kautiainen H; Rantalaiho V; Puolakka KT
J Rheumatol; 2016 Dec; 43(12):2101-2105. PubMed ID: 27909140
[TBL] [Abstract][Full Text] [Related]
5. Rheumatoid arthritis and work: The impact of rheumatoid arthritis on absenteeism and presenteeism.
Verstappen SM
Best Pract Res Clin Rheumatol; 2015 Jun; 29(3):495-511. PubMed ID: 26612244
[TBL] [Abstract][Full Text] [Related]
6. Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients.
Druce KL; Aikman L; Dilleen M; Burden A; Szczypa P; Basu N
Arthritis Res Ther; 2018 May; 20(1):96. PubMed ID: 29843776
[TBL] [Abstract][Full Text] [Related]
7. Quantifying the economic burden of productivity loss in rheumatoid arthritis.
Filipovic I; Walker D; Forster F; Curry AS
Rheumatology (Oxford); 2011 Jun; 50(6):1083-90. PubMed ID: 21245074
[TBL] [Abstract][Full Text] [Related]
8. Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis.
Puolakka K; Kautiainen H; Mottonen T; Hannonen P; Korpela M; Hakala M; Luukkainen R; Vuori K; Blåfield H; Leirisalo-Repo M
Scand J Rheumatol; 2009; 38(2):96-103. PubMed ID: 19274516
[TBL] [Abstract][Full Text] [Related]
9. Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis: does early anti-TNF therapy bring patients back to work?
Olofsson T; Petersson IF; Eriksson JK; Englund M; Nilsson JA; Geborek P; Jacobsson LTH; Askling J; Neovius M;
Ann Rheum Dis; 2017 Jul; 76(7):1245-1252. PubMed ID: 28073801
[TBL] [Abstract][Full Text] [Related]
10. [Productivity costs of rheumatoid arthritis in Germany. Cost composition and prediction of main cost components].
Merkesdal S; Huelsemann JL; Mittendorf T; Zeh S; Zeidler H; Ruof J
Z Rheumatol; 2006 Oct; 65(6):527-34. PubMed ID: 16534538
[TBL] [Abstract][Full Text] [Related]
11. Employer model of workplace impacts of anti-TNF therapy for rheumatoid arthritis.
Birnbaum H; Pike C; Kaufman R; Cifaldi M
J Occup Environ Med; 2009 Oct; 51(10):1167-76. PubMed ID: 19786900
[TBL] [Abstract][Full Text] [Related]
12. Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States.
Hone D; Cheng A; Watson C; Huang B; Bitman B; Huang XY; Gandra SR
Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1564-72. PubMed ID: 23554320
[TBL] [Abstract][Full Text] [Related]
13. Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study.
Behrens F; Tony HP; Koehm M; Schwaneck EC; Gnann H; Greger G; Burkhardt H; Schmalzing M
Clin Rheumatol; 2020 Sep; 39(9):2583-2592. PubMed ID: 32206973
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out.
Allaire S; Wolfe F; Niu J; Zhang Y; Zhang B; LaValley M
Arthritis Rheum; 2008 Aug; 59(8):1082-9. PubMed ID: 18668597
[TBL] [Abstract][Full Text] [Related]
15. Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatment-A Systematic Literature Review.
Batko B; Rolska-Wójcik P; Władysiuk M
Int J Environ Res Public Health; 2019 Aug; 16(16):. PubMed ID: 31426543
[TBL] [Abstract][Full Text] [Related]
16. Burden of rheumatoid arthritis on patients' work productivity and quality of life.
Xavier RM; Zerbini CAF; Pollak DF; Morales-Torres JLA; Chalem P; Restrepo JFM; Duhau JA; Amado JR; Abello M; de la Vega MC; Dávila AP; Biegun PM; Arruda MS; Ramos-Remus C
Adv Rheumatol; 2019 Nov; 59(1):47. PubMed ID: 31706348
[TBL] [Abstract][Full Text] [Related]
17. Productivity loss due to absenteeism and presenteeism by different instruments in patients with RA and subjects without RA.
Braakman-Jansen LM; Taal E; Kuper IH; van de Laar MA
Rheumatology (Oxford); 2012 Feb; 51(2):354-61. PubMed ID: 22179729
[TBL] [Abstract][Full Text] [Related]
18. Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study.
Tanaka Y; Yamazaki K; Nakajima R; Komatsu S; Igarashi A; Tango T; Takeuchi T
Mod Rheumatol; 2018 Jan; 28(1):39-47. PubMed ID: 28704126
[TBL] [Abstract][Full Text] [Related]
19. Predictors of work disability during the first 3 years after diagnosis in a national rheumatoid arthritis inception cohort.
Olofsson T; Petersson IF; Eriksson JK; Englund M; Simard JF; Nilsson JÅ; Geborek P; Jacobsson LT; Askling J; Neovius M
Ann Rheum Dis; 2014 May; 73(5):845-53. PubMed ID: 23520035
[TBL] [Abstract][Full Text] [Related]
20. Work ability in rheumatoid arthritis patients: a register study on the prospective risk of exclusion and probability of returning to work.
Hansen SM; Hetland ML; Pedersen J; Østergaard M; Rubak TS; Bjorner JB
Rheumatology (Oxford); 2017 Jul; 56(7):1135-1143. PubMed ID: 28371921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
